Alzheimer's disease is a devastating neurodegenerative disease eventually leading to dementia. An effective treatment does not yet exist. Here we show that oral application of the compound anle138b restores hippocampal synaptic and transcriptional plasticity as well as spatial memory in a mouse model for Alzheimer's disease, when given orally before or after the onset of pathology. At the mechanistic level, we provide evidence that anle138b blocks the activity of conducting Ab pores without changing the membrane embedded A beta-oligomer structure. In conclusion, our data suggest that anle138b is a novel and promising compound to treat AD-related pathology that should be investigated further.
Identifer | oai:union.ndltd.org:arizona.edu/oai:arizona.openrepository.com:10150/626613 |
Date | 01 1900 |
Creators | Martinez Hernandez, Ana, Urbanke, Hendrik, Gillman, Alan L, Lee, Joon, Ryazanov, Sergey, Agbemenyah, Hope Y, Benito, Eva, Jain, Gaurav, Kaurani, Lalit, Grigorian, Gayane, Leonov, Andrei, Rezaei‐Ghaleh, Nasrollah, Wilken, Petra, Arce, Fernando Teran, Wagner, Jens, Fuhrman, Martin, Caruana, Mario, Camilleri, Angelique, Vassallo, Neville, Zweckstetter, Markus, Benz, Roland, Giese, Armin, Schneider, Anja, Korte, Martin, Lal, Ratnesh, Griesinger, Christian, Eichele, Gregor, Fischer, Andre |
Contributors | Univ Arizona, Dept Med, Univ Arizona, Dept Biomed Engn |
Publisher | WILEY |
Source Sets | University of Arizona |
Language | English |
Detected Language | English |
Type | Article |
Rights | © 2017 The Authors. Published under the terms of the CC BY 4.0 license. |
Relation | http://embomolmed.embopress.org/lookup/doi/10.15252/emmm.201707825 |
Page generated in 0.0017 seconds